Physician profile
Arkady Levitan
NPI 1497709653
$1,823.18
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $121 · 2021: $523 · 2022: $320 · 2023: $381 · 2024: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $363.71 | 2019-2022 | |
| Amgen INC. | $236.35 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $164.67 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $160.98 | 2021-2024 | Rexulti |
| Abbvie INC. | $94.17 | 2021-2023 | |
| Lundbeck LLC | $92.07 | 2020-2024 | Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $78.92 | 2019 | |
| Merck Sharp & Dohme LLC | $63.60 | 2020-2023 | Belsomra |
| Kowa Pharmaceuticals America, INC. | $62.22 | 2020-2021 | |
| Almatica Pharma LLC | $61.43 | 2023 | Gralise |
| Allergan, INC. | $46.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.12 | 2021-2022 | |
| Alkermes, INC. | $44.64 | 2023 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $41.20 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $40.32 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $40.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $29.00 | 2024 | Voquezna |
| Acadia Pharmaceuticals INC | $22.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.12 | 2023 | |
| Avanir Pharmaceuticals, INC. | $20.60 | 2021 | |
| Amarin Pharma, INC. | $20.46 | 2021 | |
| Biogen, INC. | $20.45 | 2021 | |
| Hikma Pharmaceuticals USA | $19.49 | 2020 | |
| Genentech USA, INC. | $18.44 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.